1. Pink Sheet
  2. >>Geography

AstraZeneca/Daiichi Sankyo’s Enhertu To Get Lung Cancer Label For EU

 
• By Vibha Sharma

The European Medicines Agency has recommended new uses for 11 approved medicines, including an antibody drug conjugate for treating advanced non-small cell lung cancer.

Medicine and health care concept, Professor Doctor presenting report of diagnosis and recommend something a method with patient treatment, after results about the problem illness of patient.
There Are Limited Approved Therapies For NSCLC Patients With HER2 Alterations • Source: Shutterstock

Enhertu (trastuzumab deruxtecan), Daiichi Sankyo/AstraZeneca’s HER2-directed antibody drug conjugate, is on track to becoming approved in the EU for an expanded indication which will include treating patients with HER2-mutant advanced non-small cell lung cancer (NSCLC).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

What The EMA Can Teach HTA Bodies About Joint Clinical Assessments

 
• By Francesca Bruce

EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.

Moderna Pivots To Increase Focus On Cancer Amid US Vaccine Policy Changes

 
• By Joseph Haas

During its first quarter earnings call, Moderna avoided criticizing vaccine policy changes, but de-emphasized its flu/COVID-19 vaccine for those under age 50 and prioritized cancer programs.

What MAHA Means For US FDA: Prevention Is Not What You Think

 
• By Michael McCaughan

US HHS Advisor Calley Means said new pathways for root-cause treatments are part of the HHS Secretary Robert F. Kennedy Jr.’s vision for the FDA. But what most biopharma companies consider preventative medicines are not what he has in mind, nor does he seem to see those companies as part of the solution.